The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.

How is TNKase administered?

It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.

How Was TNKase approved?

The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.

How Common Are These Strokes?

In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.

TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."

What Are The Symptoms Of Ischemic Strokes?

Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.

Other symptoms include:

• Loss of coordination or clumsiness
• Blurry vision or double vision
• Dizziness or vertigo
• Nausea and vomiting
• Neck stiffness
• Mood swings or sudden personality changes
• Confusion or agitation
• Seizures
• Memory loss (amnesia)
• Headaches which are sudden and severe
• Passing out or fainting
• Coma

Are There Any Warning Signs?

While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.

With the patent on semaglutide expiring today in India, NATCO Pharma has become the first drugmaker to launch the generic version of the weight-loss drug in the country.

NATCO Pharma’s generic semaglutide injection prices start at INR 1,290 per month.

“NATCO is the first company to offer generic semaglutide in multi-dose vials with customized syringes… It is the most affordable GLP-1 currently in the Indian market as it is approximately 70 percent cheaper in cost than the pen device and 90 percent cheaper than the price of the innovator’s brand,” the Hyderabad-based company said, in a statement.

The company had received approval from the Central Drugs Standard Control Organization (CDSCO) in February 2026 to manufacture and market the drug, after a clinical comparison study.

Semaglutide works by targeting key areas of the brain involved in appetite regulation and food intake. It reduces hunger, improves satiety, and cuts down food cravings, eventually inducing weight loss.

It also improves insulin resistance and has a beneficial effect on the reduction of cardiometabolic events and risk factors.

NATCO's Semaglutide Drugs

NATCO's semaglutide drugs will be sold under brand names SEMANAT and SEMAFULL in multi-dose vial formats. It will be priced:

• INR 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants,
• INR 1,750 for the 8 mg/3 ml dose.

• INR 4,000 for 2 mg/1.5ml,
• INR 4,200 for 4 mg/3 ml,
• INR 4,500 per month for 8 mg/3 ml.

In comparison, Novo Nordisk's Ozempic and Wegovy in pen devices cost INR 8,800 and INR 10,850, respectively, per month for the starting doses.

NATCO has also signed a distribution partnership with Eris Lifesciences to co-market its therapy in India.

Other Generic Versions

Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Zydus Lifesciences are also expected to introduce their versions of semaglutide on Saturday.

Others in the pipeline include Alkem Laboratories, Torrent Pharmaceuticals, and MSN Laboratories.

With intense competition, analysts believe around 50 branded semaglutide generics will enter the Indian market within months, BBC reported.

Calling it a potential "magic-pill moment" for India, investment bank Jefferies predicted that the semaglutide market in the country could reach $1bn domestically.

Also read: CDSCO threatens action against pharma companies for promoting GLP-1 weight-loss drugs

End Of Novo Nordisk’s Patents

In January this year, Canada became the first country to lose patent protection for semaglutide. However, the country's health regulator hasn’t approved any generics so far.

Novo Nordisk is expected to lose the patent in 10 more countries, including Brazil, China, South Africa, Turkey, and Canada, by the end of 2026.

In view of losing patent, Novo Nordisk recently cut prices for Wegovy in India. The company also launched its blockbuster brand Ozempic in December.

Once affecting people who smoked tobacco, lung cancer in India is today more common among people who never smoked. The major reason: exposure to poor air, almost year-round.

Although air pollution has emerged as an important risk for lung cancer, the evidence on this issue from India is limited. To explore more on this, the All India Institute of Medical Sciences, Delhi, today announced undertaking a major study.

The study, dubbed ‘AIRCARE (Air Pollution and Cancer Research Ecosystem): Center for Advanced Research on Environmental Health and Lung Cancer Risk’, will examine the connection between the fine particulate matter 2.5 (PM 2.5) and the risk of lung cancer in the country.

PM2.5 particles, with a diameter of 2.5 micrometers or less, are approximately 30 times smaller than a human hair. It is a significant yet often unseen threat to air quality.

“India is home to some of the most polluted cities in the world, and there is an urgent need to scientifically look at the effects of pollution on people’s health. Lung cancer is one of the most common cancers among males in India, and there is a high number of non-smoking lung cancers among females and young adults,” said Dr. Abhishek Shankar, Assistant Professor, Radiation Oncology at AIIMS, who will lead the study, while addressing the media.

“It is deeply concerning that lung cancer, once assumed to be a disease mostly associated with people who smoke tobacco, is now seeing a rapid increase in incidence amongst people who do not smoke,” he added.

The expert urged the "need to implement policy and management strategies to tackle this disease and mitigate further loss of life”.

The AIRCARE Study

It will be the first-of-its-kind scientific study in India to evaluate the effects of exposure to air pollution.

About 1,615 lung cancer cases with 1,615 controls from their family members will be added to the study.

The study will employ both a cohort and case-control design to track the effects of chronic PM 2.5 exposure on lung cancer incidence across various demographics and socio-economic groups.

It will also attempt to isolate an Indian population-specific genetic imprint.

Based on the findings, the researchers aim to develop a risk- based screening model that will include both clinical and molecular components specific to the Indian population and exposure levels.

It will also identify the susceptible population among the cohort who are more at risk of developing lung cancer.

Lung Cancer And Air Pollution Risks In India

Data from the National Cancer Registry shows that lung cancer affects about 72,000 people and claims 66,000 lives every year in India -- making it one of the leading causes of cancer mortality in the country.

From a smoker’s illness, lung cancer has now emerged as a major concern due to poor air quality. Several doctors across Delhi and Maharashtra have n noted a significant increase in pulmonary cancer due to air pollution.

A 2025 study at a government hospital in North India found that 52 percent of lung cancer cases were among non-smokers.

The Indian government today constituted the National Dental Commission (NDC), in a major reform to improve the quality of dental education in the country and align it with global standards, said the Ministry of Health and Family Welfare, on the occasion of World Oral Health Day.

The government also announced three autonomous boards under the NDC and repealed the erstwhile Dental Council of India (DCI). The developments were notified on March 19, making the new framework operational from the same date, the Ministry said in a statement.

The NDC aims to introduce essential and long-overdue regulatory reforms in dental education and enhance access to affordable oral healthcare across the country.

The three autonomous bodies aim to support the functioning of the Commission. These are:

• Undergraduate and Postgraduate Dental Education Board -- to oversee dental education
• Dental Assessment and Rating Board -- to regulate accreditation and institutional assessment
• Ethics and Dental Registration Board -- to govern professional conduct and registration of dentists

The key functions of the National Dental Commission includes:

• Framing regulations to implement the provisions of the Act
• Conducting rating and assessment of dental institutions
• Evaluating human resources and promoting dental research
• Framing guidelines for fee regulation in private dental colleges
• Establishing standards for community dental care, education, research, and professional ethics

World Oral Health Day

Every year on March 20, World Oral Health Day is observed to empower people with the knowledge, tools and confidence to secure good oral health.

The 2026 theme is “A Happy Mouth is a Happy Life” raises awareness about the importance of caring for your mouth at every stage of life - from birth through later years.

"Healthy Mouth, Healthy Nation. This World Oral Health Day, let’s raise awareness and take action, practice proper brushing, reduce sugar intake, and prioritize regular dental check-ups. Your smile deserves daily care," the Ministry of Health shared in a post on social media platform X.

Also read: World Oral Health Day: Your Mouth May Signal Disease Before You Even Know, According To Doctor

"A healthy mouth is essential for a healthy body. This World Oral Health Day, let’s focus on building better habits for ourselves and our families," said Union Health Minister JP Nadda.

He called for building up "simple steps like proper brushing, limiting sugary foods, and regular dental check-ups" to maintain good oral health.

"Good oral care not only keeps our smile bright but also supports overall well-being. Let’s use this occasion to raise awareness and commit to maintaining good oral hygiene every day," he added.